debt_leverage_profile
0.21x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Moderate sensitivity; ~$300M term loan at variable rates means 200bps rise adds ~$6M annual interest expense, manageable given ~$200M+ EBITDA
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active pharmaceutical ingredient (API) sourcing from India/China presents primary chokepoint; secondary risk in European excipient supply chains
Inferred
Agent_Inference
international_expansion_readiness
Minimal exposure; ~95%+ of revenue is US-domestic, limiting sovereign currency devaluation risk materially
Inferred
Agent_Inference
geographic_footprint
Effectively US-only commercial footprint; negligible non-USD revenue exposure; currency devaluation risk near zero for top markets
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Pitolisant API sourced under license from Bioprojet; single-source dependency represents non-substitutable critical input exceeding 30% operational risk threshold
Inferred
Agent_Inference
business_model_type_primary
Specialty pharma product company; cloud disruption would cause operational delays but not revenue cessation; ERP/CRM migration 60-90 days realistically
Inferred
Agent_Inference
business_model_type_secondary
Prescription pharmaceutical sales model; cloud termination impacts back-office and analytics but field sales force continuity largely preserved short-term
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; commercial operations use standard SaaS CRM/ERP (Salesforce, SAP); no proprietary API lock-in in revenue-critical systems
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; revenue from FDA-approved drug sales to patients/payers; no investment contract structure; Howey Test risk score effectively zero
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low GDPR exposure given US-only operations; CCPA compliance required for California patient/prescriber data; standard pharma privacy framework applies
Inferred
Agent_Inference
antitrust_exposure_flag
Moderate; single-product orphan drug pricing scrutiny possible; no dominant market share across broad therapeutic categories to trigger DOJ/FTC action currently
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional prescription-fill revenue; no subscription model; multi-year payer contracts provide partial revenue visibility but remain volume-dependent
Inferred
Agent_Inference
monetization_vector
Per-prescription reimbursement from commercial insurers, PBMs, and government payers; gross-to-net adjustments of ~30-35% reduce net realized price
Inferred
Agent_Inference
pricing_architecture
WAC-based pricing with rebate/contracting layer; formulary access pressure from PBMs limits pricing power; generic entry risk post-patent is primary stress scenario
Inferred
Agent_Inference
pricing_power_rating
Moderate-low; orphan designation provides near-term insulation but PBM rebate demands and payer pushback cap net price increases to low-single-digit annually
Inferred
Agent_Inference
target_gross_margin_bracket
77.2% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; prescription access requires payer authorization; patient assistance programs are controlled cost centers, not leakage vectors
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth model; specialty pharma sales force largely built; incremental revenue from pipeline products requires modest headcount additions, not proportional scaling
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is low for existing product; new product launches add $20-40M in SG&A per launch; manufacturing COGS scales near-linearly with volume
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company operates direct specialty pharma model with no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics deteriorate as prescriber universe in sleep/epilepsy is finite (~15K neurologists); diminishing returns on sales force expansion
Inferred
Agent_Inference
network_effect_present
No meaningful network effect; drug utility is independent of user base size; no platform or data flywheel present in current business model
Inferred
Agent_Inference
asset_efficiency_ratio
16.9% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Tier 2 recession resistant; sleep disorders and epilepsy are chronic conditions requiring ongoing treatment; some vulnerability from insurance loss during downturns
Inferred
Agent_Inference
customer_segment_primary
Concentrated among specialty neurologists and sleep medicine physicians (~10-15K prescribers); top 20% of prescribers likely represent 60-70% of volume
Inferred
Agent_Inference
customer_segment_secondary
Payers/PBMs (CVS Caremark, Express Scripts, OptumRx) represent secondary customer segment; formulary decisions by top-3 PBMs control majority of commercial access
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001802665
High
SEC-EDGAR
ticker
HRMY
High
SEC-EDGAR